Adults who have heart failure with a left ventricular ejection fraction of 40% or more face a high risk of hospitalization for heart failure and cardiovascular death. People who have heart failure ...

Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...

The researchers of a recent British Medical Journal paper reviewed heart failure diagnosis and management data. Heart failure has led to considerable health and financial burdens globally, especially ...

When the heart struggles to pump efficiently, a cascade of events unfolds. Fluid accumulates in the lungs and extremities. Breathing becomes labored. Simple activities like climbing stairs or carrying ...

Advanced heart failure is when heart failure progresses to the most severe stage. When you have advanced heart failure, your blood pressure, blood flow, kidney and liver function, exercise capacity, ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

LISBON, Portugal—The results are mixed when it comes to the application of guideline-directed medical therapy (GDMT) for the treatment of heart failure (HF), two new studies have found, with one ...

Most patients with newly identified heart failure did not receive repeat heart function assessment, despite guideline recommendationsBELLEVUE, Wash., May 21, 2026 (GLOBE NEWSWIRE) -- A new ...

The combination of sacubitril and valsartan appeared superior to enalapril in the first randomized trial to generate high-quality evidence to support a drug treatment specifically for patients with ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally, sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...